By PPN News Staff
The FDA approved enasidenib (Idhifa, Celgene) to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay (Abbott Laboratories), which is used to detect specific mutations in the isocitrate dehydrogenase-2 (IDH2) gene in patients with AML.
Enasidenib is an IDH2 inhibitor that works by blocking several enzymes that promote cell growth.